Drugs for behavior disorders after traumatic brain injury: Systematic review and expert consensus leading to French recommendations for good practice  by Plantier, D. & Luauté, J.
Annals of Physical and Rehabilitation Medicine 59 (2016) 42–57Review
Drugs for behavior disorders after traumatic brain injury: Systematic
review and expert consensus leading to French recommendations for
good practice
D. Plantier a,*, J. Luaute´ b,c, the SOFMER group
aDepartment of Physical Medicine and Rehabilitation (PM&R), Neurological Rehabilitation, Rene´e-Sabran Hospital, University Hospital of Lyon, boulevard
E´douard-Herriot, 83400 Hye`res, France
b Physical Medicine and Rehabilitation, Neurological Rehabilitation, Henry-Gabrielle Hospital, University Hospital of Lyon, 69230 Saint-Genis-Laval, France
cNeuroscience Research Center of Lyon (CRNL) IMPACT team, Inserm U1028, CNRS, UMR5292, 69500 Bron, France
A R T I C L E I N F O
Article history:
Received 29 June 2015
Accepted 18 October 2015
Keywords:
Traumatic brain injury
Behavioral disorders
Neuroleptics
Antidepressants
Beta-blockers
Mood stabilizers
Benzodiazepines
Amantadine
A B S T R A C T
Objective: There are no handbook or recommendations for the use of pharmacological agents to treat
neurobehavioral disorders after traumatic brain injury (TBI). This work proposes a systematic review of
the literature and a user guide on neuroleptics, antidepressants, beta-blockers, mood stabilizers and
other medications for irritability, aggressiveness, agitation, impulsivity, depression, apathy. . .
Method: Steering, working and reading groups (62 people) were formed under the control of the French
High Authority for Health (HAS) in collaboration with the SOFMER scientiﬁc society (French Society of
Physical and Rehabilitation Medicine). Articles were searched by HAS ofﬁcers in the Medline database
from 1990 to 2012, crossing TBI and pharmacological agents. The HAS method to select, read and analyze
papers is close to the PRISMA statements.
Results: Out of 772 references, 89 were analyzed, covering a total of 1306 people with TBI. There is
insufﬁcient evidence to standardize drug treatments for these disorders. There are however some
elements to establish consensus recommendations for good clinical practice. Propranolol can improve
aggression (B grade). Carbamazepine and valproate seem effective on agitation and aggression and are
recommended as ﬁrst line treatment (Expert Consensus [EC]). There is no evidence of efﬁcacy for
neuroleptics. Their prescription is based on emergency situation for a crisis (loxapine) but not for long-
term use (EC). Antidepressants are recommended to treat depression (EC) with a higher standard of proof
for Selective Serotonin Reuptake Inhibitors (SSRI, grade B). Other products are described.
Conclusion: The choice of treatment depends on the level of evidence, target symptoms, custom
objectives, clinical experience and caution strategies.
 2015 Elsevier Masson SAS. All rights reserved.
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Behavioral disorders after traumatic brain injury (TBI) repre-
sent the main impairment for patients after their accident
[1,2]. The care management of these behavioral disorders is highly
relevant for families and society. Behaviors, such as agitation,
opposition, disinhibition, irritability, impulsiveness, bulimia,
hypersexuality, Kluver and Bucy Syndrome, hostility, aggres-
siveness, verbal and physical violence, anxiety and depression
(see Stephan et al. in this issue) require the consensus from experts* Corresponding author.
E-mail address: david.plantier@chu-lyon.fr (D. Plantier).
http://dx.doi.org/10.1016/j.rehab.2015.10.003
1877-0657/ 2015 Elsevier Masson SAS. All rights reserved.who understand the speciﬁc characteristics of people with TBI. The
pharmacological approach is highly specialized and is based on a
comprehensive clinical experience. The most recent data from
international literature suggest using beta-blockers, neuroleptics,
antiepileptics, antidepressants, benzodiazepines, amantadine and
other drugs.
The SOFMER French Society of Physical Medicine and Rehabili-
tation under the auspices of the French High Authority for Health
(HAS) decided to elaborate recommendations of good practice
(RGP), in response to the announcement in 2010 of a speciﬁc
government action plan for patients with TBI. Through a systematic
review of the literature, the objective of this work was to organize
care pathways, provide a practical care management guide and
Table 1
Grade recommendations.
Level of scientiﬁc evidence provided by
the literature (treatment studies)
Grade recommendation
Level 1 Established scientiﬁc
evidence
A
High power randomized comparative trials
Meta-analysis of randomized controlled trials
Decision analysis based on well-conducted
studies
Level 2 Scientiﬁc presumption
BLow-power randomized comparative trials
Non-randomized comparative studies
well-conducted
Cohort studies
Level 3 Low level of evidence
CCase-control Studies
Level 4 (NP4)
Comparative studies with considerable bias
Retrospective studies
Case series
Each selected item was analyzed according to the principles of critical literature
reading. Based on this literature review, the working group proposed, whenever
possible, recommendations. Depending on the level of evidence of studies on which
they are based, the recommendations have a varying degree, from A to C according
to the scale proposed by the HAS. In the absence of studies, the recommendations
are based on a professional consensus (EC, Expert Consensus Working Group).
Box 1. Literature search strategy for all types of studies.
(‘‘Brain Injuries’’ (Majr: NoExp) OR ‘‘Craniocerebral Trauma’’
(Majr: NoExp) AND ‘‘Drug Therapy’’ (Mesh) Or ‘‘Central Ner-
vous System Stimulants’’ (Mesh) OR ‘‘Methylphenidate’’
(Mesh) OR ‘‘Dopamine Agents’’ (Mesh) OR ‘‘Dopamine’’
(Mesh) OR ‘‘Amantadine’’ (Mesh) OR ‘‘Dopamine Agonists’’
(Mesh) OR ‘‘Bromocriptine’’ (Mesh) Or ‘‘Levodopa’’ (Mesh) OR
‘‘Antidepressive Agents’’ (Mesh) OR ‘‘Sertraline’’ (Mesh) OR
‘‘Fluoxetine’’ (Mesh) OR ‘‘Paroxetine’’ (Mesh) OR ‘‘Citalo-
pram’’ (Mesh) OR ‘‘tianeptine’’ (Supplementary Concept) OR
‘‘Trazodone’’ (Mesh) OR ‘‘Amitriptyline’’ (Mesh) OR ‘‘Clomip-
ramine’’ (Mesh) OR ‘‘Trimipramine’’ (Mesh) OR ‘‘Mianserin’’
(Mesh) OR ‘‘mirtazapine’’ (Supplementary Concept) OR ‘‘mil-
nacipran’’ (Supplementary Concept) OR ‘‘duloxetine’’ (Supple-
mentary Concept) OR ‘‘Iproniazid’’ (Mesh) OR ‘‘venlafaxine’’
(Supplementary Concept) OR ‘‘Cholinesterase Inhibitors’’
(Mesh) OR ‘‘Physostigmine’’ (Mesh) OR ‘‘donepezil’’ (Supple-
mentary Concept) OR ‘‘rivastigmine’’ (Supplementary Con-
cept) OR ‘‘Adrenergic beta-Antagonists’’ (Mesh) OR
‘‘Propranolol’’ (Mesh) OR ‘‘Haloperidol’’ (Mesh) OR ‘‘Metho-
trimeprazine’’ (Mesh) OR ‘‘Clozapine’’ (Mesh) OR ‘‘quetiapine’’
(Supplementary Concept) OR ‘‘ziprasidone’’ (Supplementary
Concept) OR ‘‘Anticonvulsants’’ (Mesh) OR ‘‘Valproic Acid’’
(Mesh) OR ‘‘Carbamazepine’’ (Mesh) OR ‘‘lamotrigine’’ (Sup-
plementary Concept) OR ‘‘Lithium’’ (Mesh) OR ‘‘zolpidem’’
(Supplementary Concept) OR ‘‘modafinil’’ (Supplementary
Concept) OR ‘‘Brain Injuries/drug therapy’’ (Majr) OR ‘‘Cranio-
cerebral Trauma/drug therapy’’ (Majr) AND ‘‘Meta-Analysis as
Topic’’ (Mesh) OR ‘‘Meta-Analysis’’ (Publication Type) OR
‘‘Review Literature as Topic’’ (Mesh) OR Meta-Analysis OR
Review Literature Or Quantitative Review OR ‘‘Random Allo-
cation’’ (Mesh) OR ‘‘Randomized Controlled Trials as Topic’’
(Mesh) OR ‘‘Randomized Controlled Trial’’ (Publication Type)
OR Random*’’ (Title) OR‘‘Comparative Effectiveness Re-
search’’ (Mesh) OR ‘‘Comparative Study’’ (Publication Type)
Or compar*(title) NOT ‘‘Critical Care’’ (Mesh) OR ‘‘Child’’
(Mesh) OR ‘‘Infant’’ (Mesh) OR ‘‘Pediatrics’’ (Mesh) OR ‘‘Ado-
lescent’’ (Mesh) Or Critical care OR child* OR infan* Or pae-
diatr* or pediatr* OR adolescent*.
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mendations concern adult patients with traumatic brain injury
presenting with behavioral disorders in the acute and chronic post-
traumatic stages. These patients are still hospitalized or living at
home or in an institution. The professionals concerned are
physicians, healthcare personnel from the units caring for these
patients, personnel of medico-social institutes or specialized care
networks.
The population of patients with TBI is more sensitive to
pharmacological treatments, it is a particular population and it
deserves speciﬁc studies that are difﬁcult to implement in
randomized, double-blind vs. placebo protocols. Multicenter
studies are often necessary to obtain a sample of patient large
enough and homogeneous to obtain sufﬁcient statistical power
(e.g. age, time since injury, identical measure scales and
identical concept deﬁnitions). Almost all systematic review
studies, controlled or not-controlled studies and original studies
come to the conclusion that further studies with a better
methodology are needed. The relevance of this work is a dual
one. On the one hand, proposing a systematic review of the
literature to provide therapeutic solutions according to the
available level of evidence and on the other hand bring
consensus expert opinions when studies are insufﬁcient to
draw a conclusion.
2. Methodology
According to HAS criteria, the methodology involved a total of
62 people divided into 3 working groups, and 4 stages:
 elaboration of a framework letter with questions developed by
the Steering committee (6 people: 3 professors of PM&R,
1 lawyer, 1 director of a medical structure);
 selection, analysis of the scientiﬁc literature and elaboration of a
scientiﬁc rationale by the project managers (8 people: 1 librarian,
2 HAS physicians, 1 PM&R professor, 4 PM&R physicians);
 the elaboration of recommendations, based on the scientiﬁc
rationale, by a working group (23 people: 5 project leaders PM&R
physicians, 3 psychologists, 2 people representing families,
4 PM&R physicians, including 1 professor, 4 psychiatrists,
1 director of a medical structure, 1 professor of physical
education, 1 MDPH (Departmental Home for Disabled Persons)
physician, 1 social worker, 1 lawyer);
 the critic analysis of all proposals by a reading group (30 people:
7 psychologists, including 3 professors, 10 PM&R specialists,
including a professor, a magistrate, a lawyer, a physiotherapist, a
social worker, 2 healthcare managers, 2 people representing the
families, one person representing the insurance companies, one
director of a medical structure, a psychiatrist, a physician
working in the prison system).
The HAS methodology is explained in details in this special
issue, in the editorial (see Mathe´ and Luaute´). This editorial reports
6 questions, our work focuses on drug therapeutics.
The literature research was performed by the HAS literature
research team using as the main database Medline over the 1990–
2012 period. Some additional articles related to the ﬁnal selection
but anterior to 1990 were also analyzed. Literature search
strategies are detailed in Box 1. A complimentary search was
performed covering the period up to June 2015 without using the
HAS research team. Each article selected was analyzed according to
the literature review methodology using reading grids in order to
attribute to each article a scientiﬁc level of evidence [3]. According
to the level of evidence of the studies on which they recommen-
dations are based, they have a variable grade, scored from A to C,
see Table 1.
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consensus of opinions from the experts of the working group
(Expert Consensus, EC), after having consulted the reading group.
The absence of an evidence grade does not mean that the
recommendations are not relevant and useful. It must, however,
incite teams to conduct further additional studies.
3. Results
In all, 106 references were found on ‘‘drug therapy (question 4)
and meta-analyses, systematic literature reviews, randomized
controlled studies, comparative studies’’. Out of these 16 were
selected. Regarding articles focusing on all types of studies (except
reviews, randomized controlled studies, comparative studies),
666 references were found, and 73 were selected.
The reasons for rejecting the studies were most often the
inadequate selection of the acute phase in the ICU post-injury,
including targeted articles on neuro-protection (285 rejections
total), letters to the author, comments, news, editorials (56 rejec-
tions), target studies on improving cognitive performance or on a
product stimulating recovery (64 rejections), absence or insufﬁ-
cient number of patients with TBI in the study (mixed population)
for 16 rejections, or animal studies (13 rejections). The diagrams
representing the selection process for the articles are illustrated
in Figs. 1 and 2. The greatest difﬁculty was to select articles,
treating in the purest manner possible, behavioral disorders post-
TBI and thus discard studies where the main objective was to
improve memory, attention and cognitive performance or
recovery in general. At the end, 89 references were identiﬁed
and concerned 1306 people with TBI. Results are expressed by
products and pharmacological class, including beta-blockers,
neuroleptics, antidepressants, antiepileptics, amantadine and
other drugs.Fig. 1. PRISMA ﬂow diagram of the study selection process for meta-analyzes, systematic 
items for reviews and meta-analyses [3].3.1. Use of beta-blocker: 33 patients included
The mechanism of action of beta-blockers on behavioral
disorders remains unclear. Beyond their cardiovascular actions,
beta-blockers protect against social anxiety and have been used to
treat agitation or aggressiveness post-TBI (Table 2).
Regarding the treatment of agitation or aggressiveness after TBI,
four studies, albeit older ones, are regularly listed [4–7]. No recent
studies exist. Regarding high doses of propranolol (up to 420 mg/
day), the study of Brooke et al. [4] conducted on 21 patients
showed its efﬁcacy on episodes of post-traumatic aggressiveness,
with reduced intensity for the most severe episodes, yet no
signiﬁcant changes were noted for the frequency of these episodes
(level 1 to 2, grade B).
For the other three studies, populations are heterogeneous. The
study by Greendyke et al. [7] included 9 patients treated by
propranolol but only 4 of them had TBI (level 4, grade C). For
pindolol [5,6], the populations studied included respectively 5/11
and 3/13 patients with TBI (level 4, grade C) Pindolol doses used
varied between 20 to 100 mg/day. Adverse effects to the
administration of beta-blockers are low blood pressure and
bradycardia [8,9]. Finally, a report of 2 cases [10] points to
metoprolol (level 4) but concerned stroke patients, not TBI
patients.
In France, the use of beta-blockers in this prescription context
(agitation aggressiveness) is outside of the marketing authoriza-
tion (MA) delivered. The recommended usual doses of propranolol
do not exceed 320 mg/day in cardiology.
The efﬁcacy of this product is validated by the prescription
habits of US experts [11]. In the population, often quite young, of
patients with TBI, this prescription is well tolerated and can
represent an alternative to the prescription of psychotropic drugs.
There seems to be an efﬁcacy on impulsivity. In clinical practice,reviews, randomized controlled trials, controlled trials. PRISMA: preferred reporting
Fig. 2. PRISMA ﬂow diagram of the study selection process for all types of studies (except reviews, comparative studies, meta-analyzes). PRISMA: preferred reporting items for
reviews and meta-analyses [3].
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No study was found regarding the treatment of anxiety by beta-
blockers after TBI.
Recommendations
Beta-blockers do not have a market authorization in the care
management of agitation and/or aggressiveness and/or irrita-
bility but the analysis of the literature shows that, in certain
cases, they can improve these disorders. Their prescription in
this indication must be evaluated according to each individualTable 2
Beta-blockers use, 33 people after TBI included.
Article Study description Le
ev
Brooke et al., 1992 [4] Randomized propranolol versus placebo study in
21 severe TBI agitated. Study of 18 months,
starting dose 60 mg/day to 420 mg/day
increments of 60 mg every 3 days. Study
duration: 8 weeks, the initial phase after head
injury. Overt Aggression Scale
Le
Gr
Greendyke and
Kanter, 1986 [6]
Randomized double-blind placebo crossover
study versus propranolol, in 10 patients with
organic brain disease. Beginning 80 mg/day to
520 mg/d. 4 of 9 patients are traumatic brain
injured. Subjects 25 to 75 years, inclusion of 1 to
30 years later
Le
Gr
Greendyke et al.,
1986 [7]
Randomized double-blind placebo crossover
study versus pindolol, 11 patients with organic
brain disease. Impulsive behavior, explosive.
Subjects ‘‘severely demented’’, aging 28 to 76, 5/
11 patients of TBI
Le
Gr
Greendyke, 1989 Randomized double-blind placebo crossover
versus pindolol, 13 patients with organic brain
disease. 3/13 are head injuries. Overt Aggression
Scale. Pindolol 20 mg/twice daily
Le
Grcase and based on the criteria associated with treatments
prescribed without MA on top of precautions of use related
to this therapeutic class. The use of propranolol in the treat-
ment of agitation and/or aggressiveness and/or irritability is
proposed at the dosage of 40 to 80 mg per day even if certain
studies have reported an effect with higher doses. Just like in
patients with no TBI, it is recommended to start the treatment
progressively and it is mandatory to wean from beta-blockers
progressively because of the coronary risk. It is preferable to
perform an ECG before starting a beta-blocker treatment
(Experts consensus [EC]).vel of
idence
Conclusions
vel 1 or 2
ade B
The intensity of agitation was signiﬁcantly lower in the
propranolol group (P < 0.05). No signiﬁcant difference in the
number of agitation episode. Reduced use of restraint measure in
the treated group. Absence of cognitive effect or interaction with
other treatments
Limits: fairly small population, 11 patients/10 placebo
vel 4
ade C
Reduction of aggressive behavior (P < 0.05) with no apparent
sedative effect. Hypotension or bradycardia in 7/9 patients
Limits: population heterogeneity in age, time of inclusion and
causes of the brain damage
No evaluation scale
vel 4
ade C
Signiﬁcant decrease in the number of crisis (P < 0.05). Optimal
response dose: 40 to 60 mg/day
Limits: population heterogeneity in age, time of inclusion and
causes of the brain damage. No evaluation scale
vel 4
ade C
8 of 13 patients improved without a statistically signiﬁcant
difference. Pindolol seems to decrease the verbal and physical
aggression and improve quality of life of these patients
Limits: population heterogeneity in age, time of inclusion and
causes of the brain damage
Table 3
Neuroleptics use, 52 people after TBI included.
Article Study description Level of proof Conclusions
Kim and Bijlani,
2006 [47]
Quetiapine, 25 to 300 mg to 800 mg, a 6-week open study
prospectively for 7 patients. Treatment of aggressiveness after
TBI. Any severity. Overt Aggression Scale (OAS) and Clinical
Global Impression (CGI)
Level 3
Grade C
Good efﬁcacy and tolerance of the product
Reducing irritability and aggression with improved cognitive
functioning
Akathisia in one subject
Michals et al.,
1993 [50]
Clozapine. 9 patients series with psychotic symptoms or
aggression access refractory to others treatments
Level 3
Grade C
Clozapine is useful in the treatment of psychosis and
aggressive behavior (partial improvement of strangeness,
agitation, hallucinations), despite side effects (2 seizures/
9 patients)
Noe´ et al., 2007 [46] Ziprasidone, 20 a` 80 mg/day, 5 cases reports, management of
behavioral disorders of patients with severe traumatic brain
injury (TBI) during the period of post-traumatic amnesia (PTA).
Agitated Behaviour Scale (ABS)
Level 3
Grade C
Efﬁcacy of ziprasidone in controlling agitation during the PTA
period. Despite the small size of the sample, ziprasidone
reduced symptoms of agitation quickly and with good
tolerability, safety and no side effects
Rao et al., 1985 [34] Open controlled prospective study in 26 agitated patients after
severe TBI. A group of 11 required haloperidol. Measure of the
length of coma, duration, of post-traumatic amnesia duration
(PTA), functional status, CT-scan results
Level 3
Grade C
No signiﬁcant difference in demographics, length of coma and
rehabilitation success. The duration of PTA is signiﬁcantly
longer in the group treated with haloperidol, P < 0.05
Limits: weak statistical numbers (11 subjects)
Stanislav, 1997 [35] Case study involving 3 subjects after head injury. Evaluation of
functioning differences before, during and after
discontinuation of antipsychotic drugs
Level 4
Grade C
There is a cognitive improvement of people after stopping
neuroleptics
Limits: 3 subjects only, methodological bias
Umansky and Geller,
2000 [51]
Case report. Olanzapine (20 mg/day) for psychotic
manifestations following a second severe closed-head injury
Level 3
Grade C
After 6 months of treatment the individual no longer heard
persecutory voices, had non delusional symptoms or rage
outbursts and exhibited improvements in mood, behavior and
follow up compliance
Viana Bde et al.,
2010 [49]
Case report. Olanzapine, 10 mg/day psychotic disorders after
craniocerebral gunshot wound. Delusions religious
persecution, auditory hallucinations
Level 3
Grade C
Progressive signiﬁcant regression after a month of psychotic
symptoms with the possibility to initiate a rehabilitation
program
TBI: Traumatic Brain injury.
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3.2.1. Generalities
Two reviews [12,13] hardly reported the use of neuroleptics
whereas other authors report their frequent use in behavioral
disorders post-TBI [8,9,14–20] (Table 3). Review articles underli-
ned the lack of a strong methodology and insufﬁcient level of
evidence.
According to the study conducted among expert healthcare
professionals [11,21] neuroleptics are not one of the 5 drugs most
used to treat agitation post-TBI. Haloperidol or risperidone is
used by non-experts. There are no standards or consensus
regarding the use of neuroleptics. A greater sensitivity to their
adverse effects post-TBI was described. The use of olanzapine was
suggested [13].
3.2.2. Adverse effects of neuroleptics after TBI
3.2.2.1. Neuroleptic malignant syndrome (NMS). There seems to be
a greater exposure to the risk of neuroleptic malignant syndrome
(NMS) post-TBI [22–26]. This syndrome is reported as a rare
occurrence. The use of haloperidol was most often reported for the
10 cases published [22–24,26–28]. It concerned young adults. A
case was reported under risperidone [24]. For Levy et al., [18] NMS
is not dose-dependent. Conversely, the review of 9 cases by
Bellamy et al. [29] reported the exact opposite with the onset of
neuroleptic malignant syndrome under high doses of haloperidol.
The most recent review [26], underlining the challenges in making
the diagnosis, reported that in 90% of the cases, the ﬁrst symptoms
appeared on average 10 days after the beginning of the neuroleptic
treatment. A hypodopaminergic state of the brain related to the
trauma was brought up.
3.2.2.2. Potentially noxious effects of neuroleptics on recovery
abilities. On animal models (rat) [29] haloperidol was reported
to affect recovery after damage to motor cortical areas and
interacts with the neuronal recovery process. For Wilson et al, [30]
multiple administrations olanzapine would not impact cognitive
functions, conversely to haloperidol. Another study [31] showed adeterioration of motor and cognitive performances after chronic
administration of high doses of haloperidol or risperidone. Unique
or repeated low doses of haloperidol or risperidone seem safe vs.
continuous high doses negatively affecting recovery (animal
study). A year later, the same team [32] showed that chronic
administrations (during 19 days) of low or higher doses of
haloperidol or risperidone prevented motor and cognitive recov-
ery. This effect did not seem related to the sedative properties [33],
but rather to the alteration of neurotransmitter systems.
In humans, a study conducted on 11 people [34] treated by
haloperidol after TBI vs. controls reported a signiﬁcant increase of
the duration of the post-traumatic amnesia in the treated group
(level 2). Another study [35], described a cognitive improvement of
patients after having stopped taking neuroleptics, but the study
only included 3 subjects and had potential biases (level 4). Thus,
we have several studies describing the negative interference of
neuroleptic treatments with the biological and brain plasticity
process, essence of the recovery project [15,16,18]. However, these
studies do not bring forward real evidence on a scientiﬁc level.
3.2.2.3. Neuroleptics and apathy post-TBI. No study was found
using neuroleptics post-TBI to treat apathy. Review studies on this
symptom in other neurological or psychiatric pathologies (low
level of evidence) reported an improvement of apathy in
schizophrenia, major and non-psychotic depression and Alzhei-
mer’s disease with second-generation neuroleptics [36–40].
3.2.2.4. Practical advice for the use of neuroleptics post-TBI. In the
absence of consensus proposals, the combined data of the different
studies analyzed [8,12,14,15,18–20,23,25,28,35,41–45] can deﬁne
practical rules to the speciﬁc use of neuroleptics post-TBI.
First do no harm, do not prescribe neuroleptics. If possible wait
or propose another non-pharmacological approach (institutional
and/or psychotherapeutic) or an alternative to neuroleptics: e.g.
beta-blockers, mood stabilizers. In the absence of objective
agitation or aggressiveness, it is recommended to limit the use
of neuroleptics to cases when other care management therapeutics
have failed. Regardless of the pharmacological approach taken, it is
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in the context of individual neurological recovery. Neuroleptics
might have a negative impact on neuronal plasticity, thus having a
reverse effect on the rehabilitation’s main objective.
In case of emergency and acute aggressiveness the prescription
of neuroleptics can be envisioned in the absence of contraindi-
cations.
Outside of the acute crisis or emergency situation, to start a
neuroleptic treatment, it is preferable to:
 start with a small dosage go slowly and progressively when
increasing the dosage continuously reassess the clinical presen-
tation;
 one single product at a time (monotherapy);
 be careful of interactions between products;
 monitor the epileptogenic threshold;
 the experience of TBI consequences, from awakening to the
chronic phase can alert prescribing physicians on the high
sensitivity of TBI patients to sedative drugs, the rule being the
‘‘minimum effective dose’’.
Prefer the use of an atypical neuroleptic (2nd generation) that
has less side effects [9,14,18,20,23], especially less extrapyramidal
side effects. Antipsychotics have a better beneﬁt/risk ratio.
Several authors estimate that one should not use neuroleptics
on the long term to treat aggressiveness after TBI except in case of
prior psychiatric disease [8,18,20,43–45]. The premorbid person-
ality and psychiatric history can guide the therapeutic choices.
3.2.2.5. Data per product (second generation, atypical neurolep-
tics). Some studies (Table 3) with a low level of evidence (level 3
to 4) concerned case reports reporting the effectiveness of
ziprasidone in agitation [46], quetiapine and olanzapine after
aggressiveness or post-traumatic psychosis [47–49] or clozapine
in this symptom with hematologic risks [50]. Another case report
(severe TBI) showed the efﬁcacy of olanzapine on hallucinations [51].
Recommendations
There is no sufficient evidence regarding the efficacy of neu-
roleptics in the treatment of behavioral disorders such as
irritability, aggressiveness or apathy post-TBI.
Observation: There are no ‘‘new’’ nor specific side effects
related to the use of neuroleptics post-TBI. However, there are
several specificities that need to be accounted for:
 greater exposure to neuroleptic malignant syndrome;
 sedative effect that could increase the risk of falls or
dysphagia;
 potential noxious effects on brain plasticity and thus on
the recovery potential.
In case of emergency or acute agitation and aggressiveness
crisis, the prescription of a neuroleptic can only be envisioned
in the absence of contraindications, to obtain a quick sedation
in order to protect the patient from self-harm, protect his/her
closed ones or the healthcare team. Loxapine (Loxapac*) has a
marketing authorization in its injectable form for treating
‘‘cases of agitation, aggressiveness and anxiety associated
with psychotic disorders, or certain personality disorders’’
(EC). The long-term use of neuroleptics for the treatment of
behavioral disorders in patients with TBI must be avoided due
to side effects, except in case of prior psychiatric disease (EC).
In the absence of therapeutic alternatives, the use of neurolep-
tic must respect the usual prescription guidelines of this
therapeutic class. Furthermore, in patients with TBI, it isrecommended to abide by prescription guidelines common to
the different therapeutic agents (see above). More specifically,
regarding neuroleptics it is essential to take additional pre-
cautions (EC): (i) take into account the epileptogenic risk, since
the threshold might be lower than usual, (ii) use preferentially
an atypical neuroleptic (2nd generation) because it leads to less
side effects, especially less extrapyramidal side effects, (iii) be
aware of the cardiovascular risks.
3.3. Use of antidepressants, 348 patients included
The scientiﬁc literature reporting the effects of antidepressants
after TBI is quite scarce (Table 4). The effect of these products on
mood and behavior has rarely been studied. The speciﬁc action of
antidepressants on behavioral disorders remains to be validated.
No argument in favor or against the use of antidepressants in
apathy was found. Regarding agitation and aggressiveness, the
level of evidence is low and contrasts with the relatively frequent
use of antidepressants. For depression itself, their usefulness is
more frequently demonstrated.
3.3.1. Agitation aggressiveness
Several arguments support the use of antidepressants to treat
agitation and aggressiveness. Animal studies have shown that
serotonin levels were negatively correlated to aggressiveness
[14]. Dopaminergic and noradrenergic circuits, greatly involved in
executive functions [52–55], are commonly disrupted after TBI,
which could promote the onset of behavioral disorders [56].
Conversely, antidepressants can have adverse effects and
increase confusion, sleepiness (at all stages of the care manage-
ment) and/or anxiety, induce nausea, anticholinergic effects for
some and increase the risk of suicidal attempts.
Based on a survey conducted on US medical specialists [11],
antidepressants are one of the 5 most frequently used drugs to
treat agitation in patients with TBI.
Regarding agitation and aggressiveness, articles are scarce. The
only study with a control group, sertraline (100 mg/d, 11 patients)
vs. placebo, did not show signiﬁcant effects on agitation (level 2).
But the number of patients was low and the study duration was
only 15 days [57]. According to Lombard et al. [59] the
antidepressant effect cannot be reached before  2 weeks. These
authors consider that Selective Serotonin Reuptake Inhibitors
(SSRIs) have a non-acceptable delay of action for the control of
acute agitation. A series of 13 patients with TBI [58] under
sertraline 200 mg/d without a group control, unveiled a signiﬁcant
effect on irritability and aggressiveness (level 3), whereas no effect
was noted on depression symptoms after 8 weeks of treatment. In
two patients presenting with Klu¨ver-Bucy syndrome (agitation,
hyperorality, hypersexuality) after severe TBI, the use of sertraline
up to 150 mg/d was followed by an improvement in a few days of
disorders that were resistant to other drugs [55] (level 3). For one
of these two cases, the association with a neuroleptic seemed to
have increased the effect of sertraline.
Amitriptyline is not commonly used in agitation after TBI
[14]. It is considered by some authors as the pharmacological
agent of choice in the treatment of behavioral disorders after
frontal brain damage [8]. A retrospective study comparing
20 agitated patients treated with amitriptyline to a control group
of 38 non agitated patients [54] found for patients in the stage of
post-traumatic amnesia a great efﬁcacy on agitation for
12 patients out of 17 after 7 days of treatment (beginning at
25 mg/d up to 150 mg/d, level 3). For a 32-year-old agitated
patient with TBI and bifrontal damage, amitriptyline was reported
to be effective in 2 weeks on anger bursts with an improvement of
attention [59] (level 3).
Table 4
Use of antidepressants, 348 people after TBI included.
Article Study description Level of evidence Conclusions
Ashman et al.,
2009 [62]
Randomized 10 weeks double-blind sertraline (early 25 mg up to
200 mg/day) versus placebo in 52 volunteers after TBI. Using
Hamilton Rating Scale for Depression (HAM-D).
Chronic phase: 17  14 years after the accident
Level 1
Grade A
No signiﬁcant difference between the two groups on depression
measures, anxiety and quality of life. There is an improvement of
3 scores (depression, anxiety, quality of life) in the 2 groups (59%
sertraline group, 32% placebo group)
Limits: heterogeneous population
Dinan and
Mobayed,
1992 [71]
Cohort 6-week study of amitriptyline (up to 250 mg), 13 mild TBI
with depression matched with 13 depressed patients without TBI.
Using modiﬁed Hamilton Rating Scale for Depression
Level 2
Grade C
Only 4 patients showed marked improvement in MTBI group
versus 11 in depressed patients without TBI. Depression following
MTBI is relatively resistant to tricyclic antidepressants treatment.
Amitriptyline is effective in some TBI cases
Fann et al.,
2000 [63]
Non-randomized single-blind 8-week study, sertraline 25–150 mg/
day versus placebo. 15 patients after Mild TBI in major depression,
on average 10.6 months later. Modiﬁed Hamilton Rating Scale and
DSM-III criteria
Level 3
Grade C
Statistically signiﬁcant improvement in depression, psychological
disorder, hatred, aggression and post concussive symptoms
Limits: no randomized group and single-blind
Horsﬁeld et al.,
2000 [64]
There are data that show that ﬂuoxetine is able of neuronal
remodeling
Open pilot study, ﬂuoxetine (20–60 mg/day) administered to a
group of ﬁve head injury with moderate or non-depressed
depression. Initial cognitive tests and after eight months
Level 4
Grade C
Fluoxetine improves mood, and performance on the Trail Making
Test Part A, and WAIS-III
Although ﬂuoxetine has had beneﬁcial effects on certain measures
of cognition, more work is needed to link these improvements with
the neuronal remodeling
Jackson et al.,
1985 [59]
Amitriptyline case study. 32-year-old man, severe agitation after
TBI and injury to the frontal lobes. Failure of others treatments
Level 3
Grade C
Efﬁciency in 2 weeks, with cessation of anger, agitation, without
signiﬁcant cognitive side effects. Respect for cognitive performance
Kanetani et al.,
2003 [65]
Milnacipran (30 to 150 mg/d) reuptake inhibitor of serotonin and
norepinephrine (SNRIs), to treat depression after mild to moderate
TBI. Open study of six weeks for 10 patients (4 men and 6 women)
from 28 to 74 years. DSM-IV Hamilton Scale (HAM-D). Cognitive
status was assessed by the mini mental test (MMSE)
Level 4
Grade C
On the basis of a HAM-D decrease more than 50% response rate was
66.7%, the remission rate of 44.4%. Signiﬁcantly greater
improvement in cognitive functions in patients. Milnacipran is a
safe and effective drug for depression after ECT and could be used
as ﬁrst line
Kant et al.,
1998 [58,72]
Open trial without control group, sertraline 50–200 mg/day. Using
Modiﬁed OAS scale.
13 irritable and aggressive patients after severe TBI (n = 2),
moderate (n = 6) or mild (n = 5).
Study 8 weeks, irritability and depression are evaluated every
2 weeks
Level 4
Grade C
Signiﬁcant reduction in irritability, aggression and critical access,
no effect on depressive symptoms after 8 weeks.
The SRI are useful for the treatment of irritability and aggression
after TBI, the improvement is not due to the improvement of
depressive symptoms
Limits: lack of control group. Alcohol use for 2 patients and drug
use for 1
Lee et al.,
2005 [25]
Randomized 4-week double-blind placebo study vs. sertraline or
methylphenidate and Neuropsychiatric sequelae after mild to
moderate TBI. Thirty patients, methylphenidate (5 mg/day to
20 mg/day), sertraline (25 mg to 100 mg/day) placebo. Before and
after 4 weeks, 13 tests on depression, quality of life, cognitive
performance, sleep
Level 2
Grade B
Methylphenidate and sertraline had similar effects on depressive
symptoms. Methylphenidate seems superior in improving
cognitive function and maintaining daytime alertness.
Methylphenidate also has better tolerance than sertraline
Meythaler et al.,
2001 [57]
Prospective randomized study sertraline (100 mg/day) versus
placebo in improving wakefulness and alertness after TBI in initial
rehabilitation phase. 11 patients. ABS, Agitated Behavior Scale,
Orientation Log, Galveston Orientation and Amnesia Test (GOAT)
Level 2
Grade B
Placebo and medication have the same levels of improvement for
the 3 tests. No signiﬁcant differences between the two groups
No negative effect on recovery or side effects.
Limits: small sample – Expected effects from the ﬁrst week, short
essay (2 weeks). Signiﬁcant bias
Mysiw et al.,
1998 [54]
Retrospective Amitriptyline study, 20 agitated patients with post-
traumatic amnesia stage after TBI. Orientation Group Monitoring
System
Level 4
Grade C
Signiﬁcant improvement of the agitation for 12/17 patients within
7 days after product initiation
No interaction with cognitive recovery
Newburn et al.,
1999 [66]
Retrospective case series of Moclobemide (450–600 mg/day),
26 patients with TBI and depression diagnosis
Hamilton Depression score (HAM-D)
Level 4
Grade C
Reduction of the HAM-D 81%. Fast action, 17 responders J3.
Reducing irritability scores by 57% and 39% for mental pain.
Moclobemide may be an effective treatment for major depression
after ECT, controlled studies are lacking
Perino et al.,
2001 [67]
Open prospective study of 12 weeks of citalopram (20 mg/day) and
carbamazepine (CBZ) (600 mg/day) in 20 depressed patients after
severe TBI. MIF, Brief Psychiatric Rating Scale (BPRS) and Clinical
Global Impression Scale (CGI)
Level 4
Grade C
(a) Citalopram combined with CBZ reduces depression and
behavioral disorders after TBI, P < 0.05. (b) These disorders must be
taken care of as soon as possible during the rehabilitation period.
Since combination therapy was used, it is not possible to determine
whether one or the other drug was primarily responsible of the
improvement
Rapoport et al.,
2008 [68]
Open study citalopram (20 mg to 50 mg/day) for 6 weeks and
10 weeks in 54 patients with major depression following mild to
moderate TBI
Hamilton Depression Scale (HAM-D)
Level 4
Grade C
The response rate is comparable to the results of the testing of
patients with major depression but has not had TBI
Rapoport et al.,
1999 [69]
Randomized double-blind study citalopram (20–50 mg/day) versus
placebo in 65 patients with major depression. Is continuous
treatment with citalopram prevents a relapse of depression after
TBI? Remission Score  7 for Hamilton Rating Scale. Relapse if
HAM  16
Level 2
Grade B
11 relapses of depression (52.4%)
Relative risk of recurrence of depression after TBI is 50%. It is better
to stop the treatment and secondarily take citalopram for
depression relapse
Limits: 10 versus 11 placebo subjects citalopram, 3 outputs study
including 1 for diarrhea
Slaughter et al.,
1999 [55]
Two cases of Klu¨ver-Bucy syndrome after severe TBI posing care
problem
Level 3
Grade C
Beneﬁt of the SRI to treat Klu¨ver-Bucy Sd after TBI
Teng et al.,
2001 [60]
Case study. An agitated man after severe TBI in the recovery phase.
Failure of others products. Treatment with Bupropion (Zyban)
Level 3
Grade C
The use of Zyban (150 mg/day) is not discussed in any other study.
In this case, it is the only treatment that could signiﬁcantly reduce
agitation and improve cognitive function
Wroblewski
et al., 1996 [70]
Randomized, placebo-controlled prospective crossover study
about desipramine (150–300 mg/j). 10 individuals with severe TBI
and depression. Product not commercialized in France
Level 3
Grade C
Of the 7 patients who completed the study, 6 improved on
desipramine treatment. 2 study outputs: a seizure, a manic turn
Signiﬁcant methodological ﬂaws and small sample size limited the
strength of the ﬁndings
TBI: Traumatic brain injury.
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(Zyban1) at quite high doses (150 mg/d) in a 20-year-old woman
described as very agitated after the failure of loxapine, haloperidol,
propranolol, methylphenidate, diazepam and paroxetine [60]
(level 3). This treatment cannot be recommended today based
on current scientiﬁc knowledge.
SSRIs present less side effects and a proﬁle of side effect
different from tricyclics that can generate sedation, as well as other
side effects such as cardiologic ones, anticholinergics with
constipation and urine retention, as well as lowering the
epileptogenic threshold [8,9]. Neither SSRIs nor tricyclic anti-
depressants have a marketing authorization in France for agitation
or aggressiveness.
3.3.2. Depression
The literature reviews by Alderfer et al., 2005 [52] and Fann
et al., 2009 [61] reported the best level of evidence for
noradrenergic and speciﬁc serotonergic antidepressants (NaSSAs)
for the treatment of depression. A randomized, double-blind vs.
placebo study after TBI with sertraline (25 to 200 mg/day) [62]
validated after 10 weeks of treatment an improvement in mood,
quality of life and anxiety (level 2).
Other studies already pointed out this result with sertraline
[25,63] (level 4). A study on ﬂuoxetine (Prozac1), to look for
cognitive effects and impact on brain plasticity [64], found an
improvement on mood as well as memory and attention
performances (level 4). A work on milnacipran (Ixel1, 30 to
150 mg/day) after light to moderate TBI [65] for a 6-week
duration, described an improvement of depression and cognitive
performances (level 4). This antidepressant is a selective
serotonin and norepinephrine reuptake inhibitor (SNRI). The
use of moclobemide (Moclamine1) post-TBI [66] in an open
study showed the good efﬁcacy of the product (level 4).
Regarding citalopram (Seropram1), a 2001 study [67] described
an 81% response rate after TBI (level 4). An open study on
54 patients with light to moderate TBI treated with citalopram
[68], reported a 46% response rate with a remission at 26.9%
after 10 weeks of treatment. These results are comparable to
results of patients suffering from major depression, without TBI
(level 4). A randomized, double-blind study citalopram vs.
placebo reported the limits of pursuing the treatment to avoid
depression recurrence. It is preferable to stop the treatment and
secondarily start again on citalopram in case of recurrence [69]
(level 2).
Regarding tricyclic antidepressants, a randomized, crossover
study focused on desipramine (not marketed in France) vs. placebo
[70]. The samples were small (6 patients with TBI validated the
study), (level 3). For amitriptyline, a study on 13 patients with TBI
compared to 13 patients with depression showed a 4/13 response
rate in the group of patients with TBI vs. 11/12 in the group without
TBI [71]. Authors concluded that depression after TBI was
relatively resistant to treatment by tricyclic antidepressants
(level 4).
Just like the treatment for aggressiveness, the treatment for
depression must seek the best beneﬁt/risk ratio, which tends to
prefer SSRIs rather than tricyclic antidepressants as ﬁrst line
treatment.
3.3.3. Apathy
For apathy, no speciﬁc study was found regarding this
speciﬁc symptom sometimes identiﬁed by certain authors in
cognitive functions. Apathy is often symptomatic of a depressive
state [72], antidepressants could be envisioned as an initial
treatment. The effect on awakening could also have a positive
impact.3.3.4. Other disorders
The use of paroxetine and citalopram seem interesting in the
treatment of pathological cries [73] even if results must be
validated in further studies on larger samples (level 3).
Recommendations
Antidepressants are mainly used to treat depression according
to the usual recommendations and in the framework of their
MA. In the absence of contraindications, they can be used after
TBI (EC). The prescription of antidepressants in the context of
the treatment of depression in all the stages of its progression,
must abide by the guidelines for clinical practice published by
the ANAES in 2002: ‘‘management of an isolated depressive
episode in adult outpatients’’ (EC). Specifically, it was indicated
that the choice of an antidepressant should preferentially be
based on specific criteria:
 therapeutic use of lateral effects (for example, looking
for sedation, anxiolytic effect or stimulation);
 the preferential indication of a therapeutic class in some
psychiatric comorbidities, for example Selective Seroto-
nin Reuptake Inhibitors (SSRIs) and speciﬁcally sertra-
line for obsessive compulsive disorders;
 the mixed effect SSRI + adrenergic (SSNRI) on cognitive
disorders for example milnacipran (Ixel1) at the dose of
30 to 150 mg (EC).
Observation: Antidepressants can be effective in an indirect
manner on agitation and aggressiveness when considering that
depression or anxiety are promoting factors. Amitriptyline
showed a certain efficacy on agitation from the dose of
25 mg per day. Paroxetine and citalopram can improve patho-
logical cries of certain patients after TBI. SSRIs could have a
positive impact on brain plasticity and thus on the recovery
potential. Sertraline showed some efficacy on agitation, aggres-
siveness and irritability with doses going up to 200 mg per day.
An improvement of Klu¨ver-Bucy Syndrome (agitation, hyper-
orality, hypersexuality) after severe TBI, was reported with
sertraline up to 150 mg/d. The positive effect might have been
majored by associating sertraline with a neuroleptic. In the
absence of specific indications, it is recommended to choose
the best tolerated antidepressant, the less dangerousone in case
of massive absorption, and the simplest to prescribe at an
effective dose. SSRIs, SSNRIs and other non-tricyclic, non-MAOI
antidepressant drugs are the onesmostadapted tothesecriteria.
During the awakening period, tricyclic antidepressants and
especially amitriptyline at a low dose can also be proposed to
treat agitation (EC). Antidepressants do not have a MA in France
to treat agitation and/or aggressiveness, so the prescription of
these molecules should be evaluated for each individual case
according to the criteria associated with treatments prescribed
outside of a MA on top of the usual recommendations (EC).
3.4. Antiepileptic mood stabilizers and other antiepileptic drugs,
555 patients included
3.4.1. Carbamazepine (CBZ), valproate (VPA) and phenytoin
Carbamazepine (CBZ) and valproate (VPA) are antiepileptic
agents commonly used as mood stabilizers to treat agitation after
TBI [8,12,14] (Table 5). VPA has the reputation of having less side
effects [8,14,74]. In France VPA and CBZ do not have a marketing
authorization for agitation, irritability or aggressiveness.
Studies describing cognitive side effects of VPA or CBZ after TBI
are contradictory. A review on phenytoin, CBZ and VPA from
1991 reported that these three medicines seemed to exert a
negative effect on cognitive and motor functions. These disorders
Table 5
Antiepileptics use, 555 people after TBI included.
Article Description of study Level of proof Conclusions
Azouvi et al., 1999 [80] Prospective open trial of carbamazepine (400–800 mg/day,
8 weeks) on agitation and aggressive behavior in
10 patients with a severe TBI
Agitated Behavior Scale (ABS), Katz Adjustment Scale (KAS)
for social functioning, Mini Mental Status Examination
(MMSE)
Level 3
Grade C
Statistically signiﬁcant improvement (P < 0.05) on
irritability and disinhibition in particular, the ABS and KAS
score. No global cognitive change found on MMSE scores
Carbamazepine might help to reduce agitation after TBI
Chahine and Chemali,
2006 [87]
A retrospective study about 4 young patients with
pathological laughter and/or pathological crying following
TBI. A lamotrigine treatment
Level 3
Grade C
The four patients were successfully treated with
lamotrigine
Chatham Showalter,
1996 [81]
Use of carbamazepine for 7 combative patients with
multiple trauma including TBI
Level 4
Grade C
This cohort had a clinical decrease in combativeness within
4 days after carbamazepine
Chatham Showalter and
Kimmel, 2000 [77]
Retrospective study for 22 months in a rehabilitation unit of
a group of 29 subjects for Divalproex under agitation. 23 TBI
patients, 5 strokes, 1 vasculitis
Level 4
Grade C
For 26 of the 29 patients, effective in 7 days at a dose of
1250 mg/day. An effective alternative to antipsychotics and
benzodiazepines against impulsivity and disinhibition after
brain injury
Dikmen et al., 2000 [74] Randomized double-blind study, Valproate (VPA) versus.
Phenytoin, comparison between prevention of epilepsy and
neuropsychological effects at 1 and 6 months. 279 adults
randomized within 24 hours of the injury, battery of
neuropsychological measures at 1, 6 and 12 months
Level 2
Grade B
No negative nor positive neuropsychological effects of VPA.
VPA seems to have a benign neuropsychological effects
proﬁle. However, for this study, the VPA does not prevent
post-traumatic crises
No placebo group
Gos´cin´ski et al., 1997 [82] 4 patients with post-traumatic lesions localized
bitemporally developed Kluver-Bucy syndrome
Treatment with carbamazepine
Level 4
Grade C
Several symptoms responded dramatically to
carbamazepine. A useful agent in treatment of this unusual
syndrome
Kim and Humaran,
2002 [78]
Retrospective study, 11 patients after TBI, Divalproex alone
or with other psychotropic proposed on neurobehavioral
symptoms
Level 4
Grade C
Divaproex is well-supported after TBI
Limits: heterogeneity of patients and treatments, 3 bipolar,
2 psychotics, 2 personality changes
Mattes, 2005 [84] Randomized double-blind oxcarbazepine (1200–2400 mg/
day) versus placebo for 10 weeks. 48 aggressive patients,
multiple medical causes
Global Overt Aggression rating, Overt Aggression Scale-
Modiﬁed
Level 2
Grade B
Consistent evidence in favor of oxcarbazepine, compared to
placebo (P = 0.012). Oxcarbazepine seems to bring beneﬁt to
aggressive adults regardless of the cause of the aggression.
Limits: Mixture of pathologies. 9 patients discontinued due
to adverse effects, 45 completing the study at least 4 weeks
Mattes, 2008 [89] Randomized double-blind levetiracetam (3000 mg/day)
versus placebo for 10 weeks, in aggressive patients (no TBI
study)
Overt Aggression Scale-Modiﬁed
Level 2
Grade B
Of 40 patients (20 in each treatment group), 34 completed
at least 4 weeks of treatment with double-blind medication.
There was no overall statistical evidence of levetiracetam
beneﬁt
Perino et al., 2001 [67] Open prospective study of 12 weeks of citalopram (20 mg/
day) and carbamazepine (CBZ) (600 mg/day) in
20 depressed patients after severe TBI. MIF, Brief Psychiatric
Rating Scale (BPRS) and Clinical Global Impression Scale
(CGI)
Level 4
Grade C
(a) Citalopram combined with CBZ reduces depression and
behavioral disorders after TBI, P < 0.05. (b) These disorders
must be taken care of as soon as possible during the
rehabilitation period. Since combination therapy was used,
it is not possible to determine whether one or the other
drug was primarily responsible for the improvement
Pachet et al., 2003 [86] Single case study. Effectiveness of lamotrigine to treat
aggressive and agitated behavior in a 40-year-old male who
sustained a severe TBI.
Level 3
Grade C
A substantial decrease in behavior problematic and a
signiﬁcant improvement in neurobehavioral functioning
were observed after lamotrigine treatment
Smith et al., 1994 [76] Double-blind versus placebo study, phenytoin and
carbamazepine (CBZ) prophylaxis of epilepsy after TBI.
40 of 64 patients receiving phenytoin and 42 of
127 receiving CBZ from 6 to 44 months. Neuropsychological
tests twice during a 4-week baseline period, at the end of a
4- to 5-week period of continued drug treatment or
placebo, and after 4 weeks of not receiving medication.
Attention and psychomotor tests, speed, memory, verbal
ﬂuency, emotional state
Level 2
Grade B
Patients in groups CBZ and phenytoin had a signiﬁcant
improvement (P < 0.01) on several measures of motor
performance and executive speed when stopping
medication. Both treatments appear to have negative
effects on cognitive performance, particularly the speed of
psychomotor tasks
Wroblewski et al.,
1997 [79]
Single case study. Effectiveness of valproate (VPA) on
destructive and aggressive behaviors in 5 patients after
acquired brain injury (4 TBI)
Level 3
Grade C
For these 5 cases, effectiveness in one to two weeks where
other treatments have failed. Fewer side effects, VPA
complies potential participation in rehabilitation
TBI: Traumatic Brain Injury.
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CBZ and phenytoin vs. placebo study, authors found a negative
impact on cognitive performance for these two products [76]
(level 2). Conversely, a prospective, randomized, double-blind
study comparing 279 patients with TBI receiving valproate or
phenytoin, showed that the valproate treatment did not have any
negative or positive neuropsychological effects [74] (level 1).
According to the survey conducted on US physicians [11], CBZ is
listed as the primary treatment to treat agitation after TBI. The
work conducted 10 years later [21] on agitation, anger and
irritability reported sodium valproate as the main treatment.
Regarding treatment of agitation and aggressiveness by VPA, a
prospective study on 29 patients, including 23 who presented with
TBI described an improvement in 26 patients [77]. The efﬁcacy wasdescribed as rapid, with doses comprised between 1000 and
1800 mg per day (mean 1200 mg) of sodium valproate (level 3).
For more heterogeneous disorders (bipolar, psychotic) another
retrospective study [78] reports a good efﬁcacy and good tolerance
for 11 patients after TBI (level 4). Another series of 5 subjects (4 TBI/
5) reported the efﬁcacy of VPA where other treatments had failed
[79] (level 3).
Regarding the use of carbamazepine (400 to 800 mg/day) in
10 patients agitated with anger bursts in a prospective open 8-week
study reports a good efﬁcacy [80] (level 3) with no negative cognitive
effects. A study on 7 aggressive patients with TBI reported the
efﬁcacy of carbamazepine (400 to 900 mg/day) in the 4 days
following the beginning of treatments, and in four cases CBZ was
associated with haloperidol, allowing the decrease of neuroleptics
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Bucy Syndrome after post-traumatic bilateral temporal injury,
showed a very good efﬁcacy of CBZ [82] (level 4). Finally, Perino
et al. reported the efﬁcacy of the citalopram/CBZ (600 mg/d)
combination in 20 subjects with major depression and behavioral
disorders, among the 37 subjects of a prospective open study [67]
(level 4).
3.4.2. Oxcarbazepine (OXC) (Trileptal1)
There is no study on behavioral disorders treated by OXC after TBI.
OXC appears to have an efﬁcacy similar to CBZ and less side effects in
children, adolescents and adults suffering from partial seizures
[83]. A randomized, double-blind OXC vs. placebo study (24 people
per group) brought convincing evidence of the superiority of OXC for
the treatment of aggressiveness, independently of medical causes
[84] (level 2). The same author published a focus on oxcarbazepine in
the treatment of aggressiveness in prison [85]. The search for the
slightest side effect and an efﬁcacy, even a partially proven one,
guides towards using anti-seizure drugs as ﬁrst line treatment for
aggressiveness. Nowadays, a wider use of OXC is being discussed.
3.4.3. Lamotrigine (Lamictal1)
Only one case study was found, concerning a 40-year-old patient
with severe TBI treated successfully for his aggressiveness by
lamotrigine [86] (level 3). There are 4 published cases of laughs and
spasmodic cries treated successfully by lamotrigine [87] (level 3).
3.4.4. Gabapentin (Neurontin1)
No study was found on gabapentin and neurobehavioral
disorders post-TBI. There is one published case of aggravation of
agitation after TBI associated with the prescription of gabapentin
for neuropathic pain [88].
3.4.5. Levetiracetam (Keppra1)
Another study on aggressive patients without TBI seems to
underline the lack of efﬁcacy of levetiracetam on this symptom
[89] (level 2).
Recommendations
The use of antiepileptic agents for epilepsy treatment or
prophylaxis after TBI suggests an efficacy of carbamazepine,
sodium divalproate and sodium valproate in the treatment of
agitation and aggressiveness. Carbamazepine (CBZ) (Tegre-
tol1) and sodium valproate (VPA) (Depakine1) are recommen-
ded as first line treatment after TBI to treat agitation,
aggressiveness, anger and irritability especially in the pres-
ence of mood swings. Nevertheless, the use of antiepileptic
drugs having a mood stabilizing effect, has not been validated
by a marketing authorization to treat agitation, aggressiveness,
anger and irritability and the prescription of these molecules
must be evaluated for each individual case, according to the
criteria associated with treatments prescribed outside a MA on
top of the usual precautions of use (EC).
Observation: The efficacy of VPA is described as rapid, with a
relatively standardized dose of 1250 mg of sodium divalproate.
The good efficacy of CBZ was reported with a dose of 400 to
900 mg/day without negative cognitive side effects. An im-
provement of post-traumatic Klu¨ver-Bucy syndrome was
reported for CBZ treatment. Some authors promote the use
of oxcarbazepine (OXC) (Trileptal1) instead of CBZ due to its
efficacy on agitation and aggressiveness and a better profile of
side effects. Regarding Lamotrigine (Lamictal1), an improve-
ment of aggressiveness and spasmodic cries and laughs was
reported in case studies. Levetiracetam (Keppra1) has no
positive effects on aggressiveness post-TBI. It should be avoi-
ded after TBI because of the risks of behavioral and mood
disorders induced by this drug agent (EC).3.5. Benzodiazepines
According to the survey conducted on US physicians [11],
benzodiazepines (BZD) are not used by the expert group and are
ﬁrsthand used by non-experts (5th place). The similar work dating
from 2007 [21] pointed to the same results for agitation, whereas
BZD were not listed for treating anger or irritability.
Regarding agitation and aggressiveness, the reviews described
the potential noxious effects of benzodiazepines (BZD) after a
stroke or brain damage [9]. Some bothersome side effects were
reported such as paradoxical agitation, especially in older subjects
or an amnestic effect by nature, which might promote confusion in
people in the post-traumatic amnesia. For some authors, BZD
should only be used in emergency situations and should not be
used on the long term in the treatment of agitation post-TBI [8,9]. It
is preferable to limit its use to situations where anxiety is the
predominant symptom and for episodic agitation. One should take
into account its sedative effect and its limitation with a negative
impact on cognitive recovery.
An Australian meta-analysis [90] assessed the effects of long-
term use of benzodiazepines (more than 1 year) on the normal
population, without TBI. The use reported the evidence of a global
cognitive impact on all the variables assessed (sensory processes,
memory, processing speed, attention/concentration, general intel-
ligence, work memory, psychomotor speed, problem resolution,
motor control and performances, verbal reasoning) (level 1).
Recommendations
There is not enough evidence on the efficacy of benzodiaze-
pines in the treatment of agitation or aggressiveness in
patients with TBI. BZD can be used in situation of emergency
and should not be used on the long term in the treatment of
agitation after TBI. The use will be limited to situations were
anxiety is the predominant symptom and privileging a short-
term use (symptomatic prescription) (EC). After TBI, the use of
benzodiazepines must take into account the risk to generate or
aggravate awareness, attention and/or memory disorders,
potential respiratory depression, risk of a paradoxical effect
on agitation, and its inhibition of brain plasticity capacities.
There is also a risk of dependence and addiction (EC).
3.6. Amantadine, 295 patients included
Regarding the treatment of agitation with amantadine, US
experts list this product among the 5 ﬁrst ones [11], before beta-
blockers (Table 6). Amantadine is an antiparkinsonian, antiviral
agent, which increases the availability of pre- and post-synaptic
dopaminergic markers in the striatum. It is also a NMDA (N Methyl
D Aspartate) receptor antagonists [14,25,91–95].
About aggressiveness or agitation, literature few data are
available. Two aggressive subjects with TBI were improved under
amantadine (level 3) [96]. A retrospective study on a heteroge-
neous population (including patients with TBI) reported a
spectacular improvement of 2 out of the 3 agitated subjects
(level 4) [97]. A randomized, double-blind vs. placebo, crossover
study analyzed the recovery of 10 patients in a rehabilitation
center in their acute stage [98] and concluded to the absence of
signiﬁcant difference (levels 2–3) in spite of an improvement. We
can note the reported beneﬁt of amantadine on neurological
recovery [99] with a good methodology (level 1).
For apathy, no article was found describing the use of
amantadine for this speciﬁc keyword. An article described, for a
case of severe TBI after 6 months, the use of amantadine at the dose
of 300 mg/day with success in a motivational syndrome [100]
(level 4). In a case study of 7 subjects including 6 with TBI,
Table 6
Amantadine use, 295 people after TBI included.
Article Description of study Level of proof Conclusions
Chandler et al.,
1988 [96]
Two cases of recovering brain injury patients with difﬁcult-
to-treat destructive behavior, whose agitation and
aggression responded to amantadine
Level 3
Grade C
Direct-acting dopamine agonists such as amantadine may
be the preferred treatment for patients with behavior
problems in the acute stages of recovery from coma
Hammond et al.,
2014 [115]
Double-blind randomized prospective study amantadine
200 mg/day (n = 36) versus placebo (n = 36) more than
6 months after TBI with irritability and aggression for
28 days. Using the Inventory Neuropsychiatric irritability
(NPI-I)
Level 1
Grade A
Agitation and aggression are signiﬁcantly decreased
(P = 0.0016) in frequency and severity in the amantadine
group
No difference in the occurrence of side effects between the
two groups
Hammond et al.,
2015 [116]
Double-blind, randomized, multicentre prospective study
amantadine (n = 75) 200 mg/day versus placebo (n = 82)
more than six months after TBI with irritability and for
60 days. J28 and J60 Evaluation. Using the Neuropsychiatric
Inventory (NPI-I) and Clinical Global Impression (CGI)
Level 3
Grade C
Despite a signiﬁcant improvement in the amantadine
group, there is no signiﬁcant difference between the two
groups at D28 and D60. No difference in the occurrence of
side effects between the two groups
Placebo effect may have masked the detection of a drug
effect (through observation)
Kraus et al.,
1997 [93]
Seven case series (6 with TBI, 1 with meningitis) with
‘‘frontal lobe syndrome’’ including impulsivity,
disinhibition, poor motivation. Using amantadine, 400 mg/
day. Patients received neuropsychiatric examinations and
serial neuropsychological testing
Level 4
Grade C
All patients showed some degree of positive response. One
had side effects that resolved upon discontinuation of drug
Meythaler et al.,
2002 [99]
A prospective, randomized, double-blind, amantadine
(200 mg/day) versus placebo-controlled (6 weeks),
crossover design. 35 subjects, who had a TBI with a Glasgow
Coma Scale score of 10 or less within the ﬁrst 24 hours after
admission
Level 2
Grade B
Improvement in various tests, (P < .05), in the group that
received amantadine during the ﬁrst 6 weeks, but there was
no improvement in the second 6 weeks on placebo (P > .05).
There was a consistent trend toward a more rapid
functional improvement regardless of when a patient was
started on amantadine in the ﬁrst 3 months after injury
Nickels et al.,
1994 [97]
Retrospective review of 12 subjects (10 with TBI) with brain
injury who were treated with amantadine
Level 4
Grade C
Ten of the 12 subjects exhibited some improvement in
cognitive and/or physical function while on amantadine.
Two of the three subjects with severe agitation showed
dramatic resolution of the agitation. Eight of nine low-
arousal subjects displayed an increased level of
responsiveness. Amantadine may play a role in
neurobehavioral recovery of brain injury
Schneider et al.,
1999 [98]
A prospective, randomized, double-blind, amantadine
versus placebo-controlled (2 weeks), crossover design.
Subjects were 10 adult traumatic brain injury patients in an
acute brain injury rehabilitation unit. Various cognitive
tests
Levels 2–3
Grade B
No signiﬁcant difference for amantadine versus placebo
although patients generally improved
Limits: small sample size, heterogeneous population, acute
time course, and large number of dependent variables
Van Reekum et al.,
1995 [100]
Case study. Severe amotivation, apathy, and abulia,
signiﬁcantly retard rehabilitation following severe TBI. A
double-blind, amantadine (300 mg/day) placebo-controlled
study. Four treatment periods of 2 weeks duration
Level 4
Grade C
This one case study suggests possible beneﬁt with
amantadine for patients with amotivational syndrome after
traumatic brain injury. There were no side effects
TBI: Traumatic Brain Injury.
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disorder (including impulsiveness, disinhibition and a motivation-
al syndrome) [93]. An improvement of frontal lobe disorder was
reported for all patients (level 4). Other case studies reported the
use of amantadine in the multiple etiologies of apathy including
traumatic brain injury [101] (level 3). In motivational language
deﬁcits (impaired linguistic ability, non-ﬂuent aphasia) after
stroke, amantadine could impact verbal ﬂuency [102] but there
were no patients with TBI in the study (level 4).
Furthermore, amantadine is used as a wakefulness-promoting
agent or for having a positive action on cognition
[25,49,91,92,95,103–106]. However, the level of wakefulness
and cognitive disorders has been associated with behavioral
disorders (see the other articles in this special issue).
Amantadine is used in TBI for fatigue, distraction, rigidity and
bradykinesia, to improve the level of vigilance [106,107], orienta-
tion, initiation, propositional movements, attention, concentra-
tion, processing speed, frontal lobe functioning [92,93,97] or even
motor learning [108].
Review articles are sometimes contradictory. The review by
Sawyer et al., 2008 concluded that at the dose of 200–400 mg/day,
amantadine seemed to safely improve wakefulness and cognition
after TBI [109]. According to Meyer et al., 2010, there is strong
evidence for the usefulness of amantadine to improve wakefulness
after TBI in children or adolescents [110]. Conversely, themeta-analysis of randomized controlled studies by Frenette
et al. in 2012, regarding the efﬁcacy and safety of dopaminergic
agonists (including amantadine) in traumatic brain injury,
reported a more cautious conclusion [111]. Important sources of
biases in the studies constituted a major preoccupation. Given the
absence of consensus on clinical results, the absence of evaluation
for safety of use, and the high risk of bias in the reviews reported in
this study, other research studies are needed before recommend-
ing dopaminergic agonists after severe TBI. Finally, a recently
published 4-week multicenter, randomized vs. placebo study [112]
about 184 subjects with severe TBI in a persistent vegetative state
(PVS) or minimally conscious state (MCS) 4 to 16 weeks after their
accident added to the debate. Authors described a faster recovery
under amantadine with increasing doses up to 400 mg/day in the
two groups of patients with PVS or MCS. Amantadine triggers an
increase of the functional recovery process (level 1).
Overall, in the studies analyzed, the optimal dose of amantadine
varied between 50 to 400 mg per day. An increased surveillance was
reported for patients suffering from epileptic seizures and cardiac
disorders. A brutal ending of the treatment was associated with the
onset of malignant neuroleptic syndrome in one case study [113].
Regarding the effect of amantadine on sleep, a study on
43 patients with TBI (12 were treated with amantadine, 31 made
up the control group) did not evidence changes to the amount of
sleep with this drug [114] (level 4).
Table 7
Other products use, 23 patients after TBI.
Article Description of study Level of proof Conclusions
Gualtieri, 1991 [118] Retrospective study of a series of 13 patients after TBI
stirred treated with buspirone 10–45 mg/day
Level 4
Grade C
Responders are mild TBI without motor and severe cognitive
impairment. 3 responders had post-traumatic agitation with
akathisia and 4 were restless, irritable or aggressive with
temporal lesions
Holzer, 1998 [120] Single case study. 45-year-old man, bilateral frontal
contusions. Attack behavior, failure of other
treatments. Test 60 mg of buspirone for 4 months
Level 4
Grade C
Everything is improving, he gains independence and can start a
conversation
Ratey et al., 1992 [121] Two case study, one after TBI. Aggressive explosive
behavior. Adding buspirone its treatment (nadolol,
lithium, CBZ)
Level 4
Grade C
Marked improvement after 5 mg  2 buspirone
Stanislav et al.,
1994 [35]
Retrospective study, buspirone (30–60 mg/day) for
36 months in 20 subjects aged 15 to 55 years.
10 validates only 3 months of treatment 8/10 had a TBI
Level 4
Grade C
9 of the 10 subjects had an improvement at endpoint. Buspirone
is well tolerated and can be effective in the treatment of
aggression and other maladaptive behaviors after TBI
TBI: traumatic brain injury.
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There is no sufficient evidence of the efficacy of amantadine in
the treatment of agitation, aggressiveness, and anxiety after
TBI.
Observation: An improvement of apathy, the decision-mak-
ing process or motivational disorders was reported in case
studies with amantadine at the dose of 300 mg per day.
Amantadine has no MA to treat apathy, the prescription of
this drug should be evaluated for each individual case accord-
ing to the criteria associated with treatments prescribed out-
side a MA on top of the precautions of use (EC).
The realm of publications about amantadine progresses faster
than the other drugs reported in this review. Two articles
published in 2014 and 2015, outside of the framework of this
work, which ended in 2012, already contradict the recommenda-
tions above (Table 7). The work of Hammond et al. [115] tends to
demonstrate with a high level of evidence (grade A) the efﬁcacy of
amantadine on irritability and aggressiveness at the dose of
200 mg per day. Thus, the frequency and severity of these
symptoms are decreased. It is a monocenter study. The extension
of this study on a multicenter level [116] did not validate this
result. A strong placebo effect (observation bias) was underlined in
both studies. No different adverse effect was reported in the two
studies compared to the placebo group. Amantadine was described
as well tolerated.
3.7. Other products, 23 patients included.
3.7.1. Buspirone (Buspar1)
This non-benzodiazepine treatment does not seem to have
sedative or addictive effects, interaction with anti-seizure drugs, or
lead to respiratory depression [8,13,117] (Table 7). The latency of
action before its anxiolytic effect is 2 to 3 weeks and 12 to 36 hours
to improve agitation [8]. The anxiolytic effect could improve the
agitation of certain patients who have an anxious component
[25,117].
Two retrospective studies on series of 13 and 8 patients treated
by buspirone after TBI for agitation or aggressiveness reporting
the efﬁcacy and good tolerance of the product (level 4)
[118,119]. These data are validated by two case studies
(level 3) after TBI [120,121].
Review articles on the care management of agitation or
aggressiveness reported buspirone as a possible alternative after
TBI. No new article was identiﬁed on the speciﬁc TBI population
since 1998.Recommendation
In some patients with TBI, buspirone did improve agitation,
aggressiveness and irritability. According to the relatively low
level of evidence, this treatment should not be proposed as first
line treatment. Controlled studies are necessary (EC).
3.7.2. Hydroxyzine (Atarax1)
Hydroxyzine can be used for its anxiolytic effect. This treatment
has less respiratory depression risks than other benzodiazepines.
We can note that its administration is counter indicated in patients
with cognitive disorders or confusion syndrome due to the risk of
aggravation related to the pharmacodynamics of the product.
3.7.3. Use of hormonal agents
Only one review brought up hormonal agents in the treatment
of agitation post-TBI, when the clinical symptoms are expressed as
sexual disinhibition [8].
A case study reported the good efﬁcacy of medroxyprogesterone
[122] in a man with hypersexual behavior (level 3). A study on
40 men including 5 patients with TBI treated with medroxypro-
gesterone after sexual aggression, compared the rate of aggression
recurrences to a control group of 21 untreated men. The study
showed a recurrence rate of 18% under progesterone vs. 58% without
treatment (level 3). However, the study was not targeted for TBI
patients. Another article reported a good efﬁcacy of estrogens on one
case in episodes of aggression in general (not just sexual aggression)
[123] (level 3).
4. Discussion
Generally, the level of evidence (in the HAS sense) to promote
the use of medications to improve behavioral disorders after TBI is
quite low. The efﬁcacy of beta-blockers and mood stabilizers
antiepileptic agents appears more adequate for irritability and
aggressiveness. These products could be administered as ﬁrst line
treatment in the absence of contraindications, associated with a
non-pharmacological care management. Neuroleptics and anti-
depressants remain useful but as a second-line treatment.
Neuroleptics keep their place as ﬁrst line treatment in emergency
cases but will be relayed by a mood stabilizer or beta-blocker
outside of a documented psychiatric context. Antidepressants,
especially SSRIs are useful in depression after TBI. Amantadine can
be used after individual case assessment in apathy or irritability
and aggressiveness. Buspirone and hydroxyzine are alternative
medications. The choice of the molecule must be discussed
Table 8
Implementation tips of drug treatment for a behavioral disorder after traumatic
brain injury (TBI).
First do no harm
Replace the problem of the effectiveness of the treatment on symptoms in the
context of neurological recovery. If possible wait or suggest a non-
pharmacological approach (institutional and/or psychotherapeutic).
Regardless of the pharmacological approach or symptom to treat, avoid
antipsychotics and benzodiazepines. Preferring when possible a drug
potentially promoting neural recovery
Customized prescription
Identify the primary target symptom (irritability, aggression, depression,
apathy.) and any disorders or symptoms or secondary objectives associated
with the treatment that could be treated with a single product or product
selection guide (mood regulation, anxiety, tremors, migraines, epilepsy
prevention, hypertension, obesity, diabetes, previous stroke, psychiatric
history, premorbid personality, dysuria. . .)
Regardless of the target symptom
Choose a product usually well tolerated
Observe the interactions between products
Consider the seizure threshold
Consider the potential cardiovascular risk
Start with a low dose (special sensitivity to psychotropic after TBI)
Go slowly and gradually when increasing doses
Re-evaluate the clinical presentation continuously
Only one product at a time (monotherapy)
Go for the minimally effective dose
Preference drug
Prefer a beta-blocker (propranolol) in case of irritability, restlessness or
aggressiveness (B grade) or an antiepileptic mood stabilizer in case of
prevention of epilepsy associated (expert agreement) or bipolar disease
Prefer using an inhibitor of serotonin reuptake (best risk/beneﬁt ratio) in the
treatment of post-traumatic depression (sertraline) with or without anxiety
(B–C grade)
Reserve the use of neuroleptics to the treatment of acute aggressive crisis
(loxapine) and treat in the shortest possible time by implementing an
alternative drug treatment or non-pharmacological one. The use of
neuroleptics is conceived on the long term only if there is a documented
psychiatric illness. Prefer the use of an atypical antipsychotic (second
generation, for example olanzapine) because of lesser side effects especially
extra pyramidal ones (expert consensus)
Apathy may be decided on case by case scenario to be treated with
amantadine (expert consensus)
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associated signs or objectives (e.g. anxiety, prevention of
epilepsy, high blood pressure, and mood stabilizer), potential
collateral effects and level of emergency. This requires a
personalized and multidisciplinary care management. Why
prescribe levetiracetam to prevent epilepsy in people with TBI
who potentially have behavioral disorders when the negative
effects of this product on behavior are widely known. The
prescription of a mood stabilizer antiepileptic drug is more
clinically appropriate.
With any treatment, the dosage increase or decrease must be
progressive due to an increased sensitivity of TBI patients to
psychotropic drugs. In the absence of adverse effects, it
is important to increase the treatment to its maximum
dosage before concluding to its lack of efﬁcacy and changing
molecule.
The approach of behavioral disorders after TBI must be a
multidisciplinary one, in order to better understand the symptom
and deﬁne the best strategy [12,14,124] (see Wiart et al. and
Luaute´ et al. in this issue). It will also help take into account
parameters like pain and a non-pharmacological psychotherapeu-
tic and/or institutional approach. It is better to prescribe
medications with no evidence of their efﬁcacy but that are well
tolerated, rather than medications with evidence of their absence
of efﬁcacy and that are poorly tolerated.
Recommendations regarding drug therapeutics must abide
by updated prescription conditions of the summary of product
characteristics (SPC) or legal mentions of the listed products.
These prescription conditions are established in France, by the
French Agency for Drugs and Health Products safety (Agence
nationale de se´curite´ du me´dicament et des produits de sante´
[ANSM]) or recent books or prescription databases. These books
describe contraindications, precautions and conditions of use of
the products, their adverse effects, monitoring to be imple-
mented and recommendations to take. In this article, only the
speciﬁcities related to the population of patients with TBI were
reported.
The use of these medications in France is most often done
outside of a Marketing Authorization (MA). The prescription must
be within a legal framework related to the reinforcement of the
safety of Drugs and Health Products [125]. MA extensions could be
discussed for the speciﬁc population of patients with TBI for
propranolol and amantadine speciﬁcally.
5. Conclusion
This study’s originality is to group together the results of a
systematic review of medication care management of behavioral
disorders after TBI, and the advice of a multidisciplinary group of
62 people steered by a Scientiﬁc Society, the French Society of
Physical and Rehabilitation Medicine (SOFMER) and the French
High Authority for Health (HAS). If scientiﬁc evidence is lacking,
because of the problematic of the studies’ methodology and the
speciﬁcity of the targeted statistic population, experts’ advice must
take over and bring a response to scientiﬁc studies that come to the
conclusion (rightly so) that further studies are needed with better
methodologies. The future will be rich of these new studies but,
like beta-blockers, used commonly in the United States after TBI,
for which the last published study dates back from 1992, the
scientiﬁc community, healthcare professionals and above all
patients and their family are waiting for these studies and
hypothetical scientiﬁc evidence.
Relevant prescriptions in the framework of behavioral disorders
after TBI was the pragmatic objective of this work (see Wiart et al.,
Luaute´ et al. in this issue). A listing of advice for prescribing
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